Aneurysmal subarachnoid haemorrhage is a complex pathology, the pathophysiology of which is still imperfectly understood. Its morbidity and mortality remain significant. In addition to the damage sustained by the brain in the immediate aftermath of aneurysmal rupture, which is inaccessible to life-saving treatment, a significant proportion of lesions occur at a distance from the initial event. Delayed cerebral ischaemia is one of the most morbid complications. It combines an inflammatory pattern with vascular dysfunction and neuronal excitotoxicity, leading to avoidable secondary neuronal loss. Vascular dysfunction is mediated by a loss of homeostasis between endothelial cells and figurative blood cells, including platelets. However, the interrelationship between these elements and the precise chronology of the dysfunction remain imperfectly described to date. It therefore seems appropriate to propose temporal monitoring of platelet activation kinetics over time, combined with concomitant collection of markers of endothelial damage, in order to clarify the vascular chronobiology of this pathology.
Study Type
OBSERVATIONAL
Enrollment
90
During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
Anaesthesiology and Intensive Care medicine department, Pierre Wertheimer hospital
Bron, Auvergne-Rhône-Alpes, France
Neurovascular intensive care unit department, Pierre Wertheimer hospital
Bron, Auvergnes-Rhones-Alpes, France
The difference in the percentage of platelets expressing P-selectin, reflecting their irreversible activation.
To describe the temporal kinetics of the percentage of activated platelets over time between patients with aHSA compared with the control group, consisting of patients with spontaneous intraparenchymal haematomas. Platelet cell activation is defined by the concomitant presence of the following markers: P-Selectin (CD-62); Gp Integrin Alpha IIb Beta 3 (CD-41); phosphatidylserine. A mixed effects linear regression model will be used for data analysis.
Time frame: Day of blood sample (inclusion visit) Day 3, day 5, day 7 and day 10 after inclusion visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.